Advancing Cardio-Oncology in Asia

Abstract

Author's summary In recent years, there has been growing interest in the subspecialty of cardio-oncology worldwide. With the growth in cardiovascular and cancer burden in Asia, there is a greater need for cardio-oncology awareness among physicians managing this unique group of patients and need to develop country-specific cardio-oncology initiatives. In this state-of-the-art review, we sought to describe the epidemiology of cancer and cardiovascular disease burden in Asia, a region with rich cultural and socio-economic diversity. From describing the uniqueness and challenges in establishing cardio-oncology in Asia, and ways to overcome any barriers, this article aims to advance the field of cardio-oncology in this part of the world.

Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology

“…Because patients with PCa live longer nowadays thanks to advances in therapy, consideration of the potential CV risk of ADT and AR axis-targeted therapy is essential for optimizing patient care in the long term. This notion aligns with the development of cardio-oncology, an emerging subspecialty aimed at improving outcomes for patients on anticancer treatment with potential cardiotoxicity (3). With the expanding older population and the growing burdens of PCa and CV diseases (CVDs) in the Asia-Pacific region (4,5), the awareness of cardio-oncology should be promoted among clinicians.…”

Editorial: Cancer treatment-related cardiovascular disease - real world data in cardio-oncology

“…With improving outcomes and survival and cure rates, the significance of cancer treatment-related cardiovascular disease (CTRCD) or toxicity (CTR-CVT) is also being realized ( 1 , 2 ). The crux of cardio-oncology is to understand such interactions better, to reduce their morbidity and mortality, and to develop protocols and guidelines to manage CTRCD through collaborative efforts in the clinic and research ( 2 , 3 ). The Global Cardio-oncology Registry has initiated multinational collaboration and has prioritized research on CTRCD in the setting of breast cancer, hematological cancers, and immune-checkpoint inhibitors (ICI) ( 4 ).…”